Video Experimental Relacionado
Updated: Feb 26, 2026
10:37
Development of Recombinant Proteins to Treat Chronic Pain
Published on: April 11, 2018
10.0K
Inhibidor de la IL-4Rα para la enfermedad atópica
Howard Y Chang1, Kari C Nadeau1
1Stanford University School of Medicine, Stanford University, Stanford, CA, USA.
Cell
|July 15, 2017
Resumen
Dupilumab, un anticuerpo monoclonal, trata eficazmente la dermatitis atópica mediante el bloqueo de las citoquinas inflamatorias clave IL-4 e IL-13. Esta terapia dirigida ofrece una nueva opción para el tratamiento del eczema.
Área de la Ciencia:
- Inmunología
- Dermatología
- Farmacología
Sus antecedentes:
- La dermatitis atópica (eczema) es una afección inflamatoria crónica de la piel impulsada por respuestas inmunes de tipo 2.
- La interleucina-4 (IL-4) y la interleucina-13 (IL-13) son las citoquinas clave que median la inflamación de tipo 2.
- Dirigirse a estas citoquinas ofrece una estrategia terapéutica potencial para la dermatitis atópica.
Objetivo del estudio:
- Para describir dupilumab, un nuevo agente biológico dirigido a la subunidad alfa del receptor IL-4.
- Resaltar el mecanismo de acción de dupilumab en el bloqueo de la señalización de IL-4 y IL-13.
- Proporcionar información sobre la aprobación y la aplicación de dupilumab para el tratamiento de la dermatitis atópica.
Principales métodos:
- Dupilumab es un anticuerpo monoclonal completamente humano (IgG4).
- Se dirige específicamente a la subunidad alfa (IL-4Rα) compartida por los receptores IL-4 e IL-13.
- Este bloqueo inhibe las vías de señalización aguas abajo de estas citoquinas críticas.
Principales resultados:
- El dupilumab inhibe eficazmente las vías de señalización de la IL-4 y la IL-13.
- Estas vías son fundamentales para la respuesta inflamatoria de tipo 2 implicada en la dermatitis atópica.
- Se ha demostrado la eficacia clínica de dupilumab en el tratamiento de la dermatitis atópica.
Conclusiones:
- Dupilumab representa un avance significativo en el tratamiento de la dermatitis atópica.
- Al dirigirse a los factores clave de la inflamación de tipo 2, ofrece un enfoque terapéutico específico.
- La aprobación de dupilumab ofrece una nueva opción biológica para pacientes con eczema de moderado a severo.
Videos de Conceptos Relacionados
01:19Antiasthma Drugs: Leukotriene Modifiers
2.0K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.0K
01:24T Cell Types and Functions
2.8K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.8K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.0K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.0K
01:30Asthma-IV: Diagnostic and Management
3.2K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.2K
01:17Drugs Used in Lower Respiratory Disorders: Overview
1.3K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.3K